United States STD Diagnostics Market Report by Test Type, Technology, Location of Testing, End User, States and Company Analysis 2025-2033
Buy NowUnited States STD Diagnostics Market Size and Forecast
United States STD Diagnostics Market is projected to grow from US$ 5.06 Billion in 2025 to US$ 8.48 Billion by 2034, registering a Compound Annual Growth Rate (CAGR) of 5.91% during 2026–2034. The market is expanding due to increasing awareness of sexually transmitted diseases, rising demand for early and accurate diagnosis, and greater adoption of advanced molecular testing technologies. Growing screening initiatives, improved healthcare infrastructure, increasing availability of rapid testing, and government-supported disease-control programs are further supporting market growth across the United States.
What is the United States STD Diagnostics Market and Its Uses & Popularity
United States STD Diagnostics Market comprises diagnostic tests, instruments, reagents, and services used to detect sexually transmitted diseases (STDs), including chlamydia, gonorrhea, syphilis, HIV, herpes, and trichomoniasis. Testing is performed through blood, urine, vaginal, throat, and rectal samples, using molecular, serological, rapid, and laboratory-based technologies. The market supports screening, early diagnosis, treatment monitoring, prenatal care, and public-health surveillance. Demand remains strong because many STIs can occur without noticeable symptoms, making routine testing essential. In 2023, the United States reported more than 2.4 million combined cases of chlamydia, gonorrhea, and syphilis, highlighting the continuing need for accessible diagnostics. CDC recommendations encourage routine screening for several higher-risk populations, including sexually active women under 25 and sexually active gay and bisexual men. The availability of self-testing and self-collection options is also increasing accessibility. In 2024, the FDA authorized the first over-the-counter at-home syphilis antibody test, further supporting consumer-focused diagnostic adoption.
USA States with Highest STD Rates
1. Mississippi – Highest STD Rate
Mississippi ranked 1st among U.S. states, with 1,784 STD cases per 100,000 population and 48,183 total reported cases. The state recorded 23,919 chlamydia cases, 13,773 gonorrhea cases, 778 syphilis cases, and 9,713 HIV cases.
2. Louisiana – High Overall Infection Burden
Louisiana ranked 2nd, reporting 1,718 STD cases per 100,000 population and 70,627 total cases. Reported infections included 32,997 chlamydia cases, 15,483 gonorrhea cases, 767 syphilis cases, and 21,380 HIV cases.
3. Georgia – Significant STD Case Volume
Georgia ranked 3rd, with an STD rate of 1,535 cases per 100,000 population. The state recorded 145,445 total cases, including 62,582 chlamydia, 23,463 gonorrhea, 1,839 syphilis, and 57,561 HIV cases.
4. New York – Large Absolute Case Numbers
New York ranked 4th, with 1,512 STD cases per 100,000 population and 268,674 total reported cases. The statistics included 97,722 chlamydia cases, 42,517 gonorrhea cases, 3,052 syphilis cases, and 125,383 HIV cases.
5. Maryland – Elevated STD Rate
Maryland ranked 5th, recording 1,449 STD cases per 100,000 population and 78,779 total cases. The state reported 32,398 chlamydia cases, 12,052 gonorrhea cases, 904 syphilis cases, and 33,425 HIV cases.
6. South Carolina – High Chlamydia and Gonorrhea Burden
South Carolina ranked 6th, with 1,438 STD cases per 100,000 population and 69,408 total cases. It recorded 34,118 chlamydia cases, 16,705 gonorrhea cases, 671 syphilis cases, and 17,914 HIV cases.
7. Florida – Large Diagnostic Demand
Florida ranked 7th, with 1,355 STD cases per 100,000 population and 259,033 total reported cases. The state recorded 100,030 chlamydia cases, 40,788 gonorrhea cases, 3,674 syphilis cases, and 114,541 HIV cases, creating substantial demand for STD testing and diagnostics.
8. North Carolina – Substantial Reported Infections
North Carolina ranked 8th, with 1,299 STD cases per 100,000 population and 127,813 total cases. Reported infections included 64,640 chlamydia cases, 28,258 gonorrhea cases, 1,353 syphilis cases, and 33,562 HIV cases.
9. Nevada – Elevated Rate per Population
Nevada ranked 9th, recording 1,260 STD cases per 100,000 population and 32,958 total reported cases. The state reported 14,739 chlamydia cases, 6,364 gonorrhea cases, 813 syphilis cases, and 11,042 HIV cases.
10. Alabama – High Rate and Continued Testing Need
Alabama ranked 10th, with 1,235 STD cases per 100,000 population and 56,209 total cases. Reported infections comprised 27,075 chlamydia cases, 14,426 gonorrhea cases, 550 syphilis cases, and 14,158 HIV cases.
Growth Driver in the Market
High STI Burden and Increasing Need for Early Diagnosis
The substantial burden of sexually transmitted infections is a major growth driver for the United States STD diagnostics market. In 2023, more than 2.4 million cases of chlamydia, gonorrhea, and syphilis were reported nationally, including approximately 1.65 million chlamydia cases, 601,000 gonorrhea cases, and 209,000 syphilis cases. Although provisional 2024 data showed an 8.5% decline in the combined number of these three infections, the total remained above 2.24 million cases, demonstrating continued demand for screening and diagnostic services. Chlamydia remains particularly important because infections are frequently asymptomatic; CDC data indicate that 55.8% of reported chlamydia cases in 2023 occurred among people aged 15–24 years. Consequently, healthcare providers increasingly rely on molecular diagnostics and routine screening to identify infections before complications or transmission occur. Rising awareness, sexual-health campaigns, and greater emphasis on preventive healthcare are therefore supporting continued utilization of STD diagnostic technologies across the United States.
Expansion of Screening Programs and Preventive Healthcare
Growing adoption of routine STI screening represents another important growth driver. The CDC recommends annual chlamydia and gonorrhea screening for sexually active women younger than 25, with screening also recommended for older women at increased risk. Sexually active gay and bisexual men are advised to receive screening for syphilis, chlamydia, and gonorrhea at least annually, with testing every three to six months for those at higher risk. Pregnancy is another significant diagnostic setting, as CDC guidance recommends syphilis screening for all pregnant women at the first prenatal visit, with additional testing for those at elevated risk. These recommendations create recurring demand for laboratory tests, molecular assays, serological diagnostics, and specimen-collection products. In addition, STI testing is increasingly incorporated into primary care, reproductive health, sexual-health clinics, and community programs. Broader preventive-care initiatives and greater recognition of asymptomatic infections are encouraging earlier testing, supporting the sustained expansion of the U.S. STD diagnostics market.
Adoption of Rapid, At-Home, and Molecular Diagnostic Technologies
Technological advancement is transforming STD diagnostics in the United States by making testing faster, more convenient, and increasingly accessible outside conventional laboratories. Molecular diagnostic methods, particularly nucleic acid amplification tests, provide sensitive detection of infections such as chlamydia and gonorrhea and support testing from multiple specimen types. At-home and self-collection approaches are also expanding consumer access. According to the CDC, Americans can currently use FDA-approved self-test options for HIV and syphilis, while FDA-approved self-testing is also available for gonorrhea, chlamydia, and trichomoniasis in certain circumstances; self-collection kits can be used for laboratory testing of HIV, syphilis, chlamydia, and gonorrhea. In August 2024, the FDA authorized the first over-the-counter at-home test for syphilis antibodies, an important milestone for decentralized testing. These innovations can reduce barriers related to clinic visits, privacy concerns, and geographic access, thereby supporting broader testing participation and market growth.
Challenges in the Market
Limited Awareness and Persistent Stigma Around STI Testing
Social stigma, privacy concerns, and insufficient awareness remain significant challenges for the U.S. STD diagnostics market. Many sexually transmitted infections can remain asymptomatic, meaning individuals may not recognize the need for testing or may postpone diagnosis because they feel healthy. The CDC specifically notes that STIs often have no symptoms and emphasizes testing even when individuals do not experience noticeable signs. Stigma surrounding sexual health can further discourage individuals from discussing sexual histories with healthcare providers or visiting dedicated STI clinics. This can reduce screening participation and delay diagnosis, particularly among populations that already experience barriers to healthcare access. The CDC’s 2023 surveillance data also demonstrate substantial disparities: 48.2% of reported chlamydia, gonorrhea, and syphilis cases occurred among people aged 15–24, while 32.4% of reported cases occurred among non-Hispanic Black or African American people, compared with 12.6% of the U.S. population. Improving education, confidentiality, affordability, and culturally appropriate testing services remains important for expanding diagnostic adoption.
Unequal Access and Cost-Related Barriers
Unequal access to healthcare services, diagnostic facilities, and affordable testing can constrain market expansion, particularly among underserved populations. STI diagnosis may require clinical consultations, laboratory infrastructure, trained personnel, specimen collection, and follow-up care, which can create barriers for people without adequate insurance coverage or convenient healthcare access. The CDC highlights that STI disparities can reflect differences in access to quality sexual-health care as well as differences in sexual networks and community prevalence. Geographic differences can also make laboratory-based testing less convenient for individuals in rural or underserved communities. Although self-testing and self-collection technologies are improving accessibility, not every STI has an equivalent at-home testing option, and some positive results require confirmatory or clinical testing. For example, the FDA notes that the at-home syphilis antibody test authorized in 2024 cannot by itself establish a current infection and requires follow-up testing. Therefore, affordability, accessibility, confirmatory testing requirements, and healthcare-system capacity remain important challenges.
STD Diagnostics Launches in USA
- Visby Medical Women’s Sexual Health Test – 2025
Visby Medical received FDA marketing authorization for its Women’s Sexual Health Test in March 2025. It is the first nonprescription, fully at-home diagnostic test for chlamydia, gonorrhea, and trichomoniasis, with results available in approximately 30 minutes. - Roche cobas liat STI Multiplex Assay – 2025
Roche received FDA clearance and a CLIA waiver for its cobas liat STI molecular tests in January 2025. The PCR-based tests provide results in about 20 minutes and support decentralized testing for chlamydia, gonorrhea, and other STIs. - Roche cobas liat CT/NG/MG Nucleic Acid Test – 2025
Roche’s cobas liat CT/NG/MG test received FDA clearance in January 2025. The molecular assay detects Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium, expanding rapid multiplex STI diagnostic capabilities in U.S. healthcare settings. - Roche cobas liat CT/NG Nucleic Acid Test – 2025
Roche’s cobas liat CT/NG test received FDA clearance in January 2025. The molecular diagnostic is designed for detection of chlamydia and gonorrhea and supports rapid point-of-care testing, helping healthcare providers make treatment decisions during the same visit. - Abbott simpli-COLLECT STI Test – 2025
Abbott Molecular’s simpli-COLLECT STI Test received FDA 510(k) clearance in January 2025. The system is designed for nucleic-acid detection of nonviral microorganisms causing STIs using specimens collected at home, supporting the growing U.S. trend toward decentralized and self-collection-based diagnostics. - First To Know Syphilis Test – 2024
NOWDiagnostics received FDA marketing authorization in August 2024 for the First To Know Syphilis Test, the first over-the-counter at-home test for detecting antibodies associated with Treponema pallidum. The test provides an initial indication that requires follow-up diagnostic testing. - LetsGetChecked Simple 2 Test – 2023
The FDA authorized LetsGetChecked’s Simple 2 Test in November 2023 for at-home sample collection for chlamydia and gonorrhea. It became the first FDA-authorized STI diagnostic, other than HIV, allowing patients to collect samples at home for testing. - Visby Medical Sexual Health Test – Expanded STI Testing
Visby Medical’s molecular Sexual Health Test represents a major advancement in decentralized STI diagnostics, combining detection of chlamydia, gonorrhea, and trichomoniasis in a single platform. The FDA’s 2025 authorization created a new regulatory pathway for similar home STI diagnostics. - Abbott Alinity m STI Assay – Multiplex Molecular Testing
Abbott’s Alinity m STI Assay supports multiplex molecular detection of chlamydia, gonorrhea, trichomoniasis, and Mycoplasma genitalium. Its inclusion in the FDA-cleared molecular-testing landscape demonstrates continued expansion of multiplex laboratory diagnostics for STI management in the United States. - Hologic Aptima STI Testing Portfolio – Molecular Diagnostics
Hologic’s Aptima platform includes FDA-cleared molecular assays for chlamydia and gonorrhea, supporting high-throughput laboratory STI testing. The Aptima portfolio is part of the established U.S. molecular diagnostics landscape and demonstrates the continued shift toward sensitive nucleic-acid-based STI detection.
High Disease Burden Supporting Testing Demand
The USA Chlamydia Testing Diagnostics Market is supported by the continuing prevalence of Chlamydia trachomatis infections and the importance of routine screening. In 2023, the United States reported 1,648,568 chlamydia cases, equivalent to 492.2 cases per 100,000 population, making chlamydia the most frequently reported nationally notifiable STI. Approximately 55.8% of reported cases occurred among people aged 15–24, demonstrating particularly strong demand for testing among adolescents and young adults. Chlamydia is frequently asymptomatic, increasing the importance of screening-based diagnosis rather than symptom-driven testing. The widespread use of nucleic acid amplification tests (NAATs), which provide sensitive detection from urine and swab specimens, supports the market’s expansion. Although provisional 2024 data showed reported cases declining 8% to approximately 1.52 million, the disease burden remains substantial. Continued screening recommendations, reproductive-health visits, sexual-health clinics, and public-health programs sustain demand for laboratory and point-of-care diagnostic solutions. Rising awareness of untreated infection risks and increasing access to convenient testing are further supporting diagnostic utilization across the United States.
Growing Screening and Cancer-Prevention Requirements
The USA HPV Testing Diagnostics Market is driven primarily by the role of human papillomavirus testing in cervical cancer prevention and screening. Persistent infection with high-risk HPV types is responsible for the majority of cervical cancer cases, making molecular HPV testing an important component of preventive healthcare. HPV testing is increasingly incorporated into cervical cancer screening alongside cytology and, in appropriate age groups, primary HPV testing. The American Cancer Society recommends that people at average risk begin cervical cancer screening at age 25, with primary HPV testing every 5 years as the preferred option where available. HPV testing also supports follow-up of abnormal cervical screening results and identification of individuals requiring additional evaluation. Advances in molecular diagnostics have improved test sensitivity, automation, and laboratory efficiency, while self-collected vaginal specimens are creating additional opportunities to reach people who face barriers to conventional screening. Growing awareness of HPV-related cancers, vaccination programs, preventive healthcare initiatives, and demand for earlier risk identification continue to strengthen the U.S. HPV diagnostics market.
Increasing Adoption of High-Sensitivity Molecular Testing
USA STD Molecular Diagnostics Market is expanding as healthcare providers increasingly favor highly sensitive molecular methods for detecting sexually transmitted infections. Nucleic acid amplification testing is particularly important for chlamydia and gonorrhea because infections may be asymptomatic and require laboratory confirmation. The scale of the U.S. STI burden creates substantial testing requirements: more than 2.2 million combined cases of chlamydia, gonorrhea, and syphilis were reported in 2024, according to provisional national surveillance data. Molecular diagnostics can analyze specimens collected from urine, genital, rectal, and pharyngeal sites, enabling broader screening among different patient populations. Multiplex platforms can also detect multiple pathogens from a single specimen, improving testing efficiency and supporting faster clinical decision-making. Technological development is expanding beyond centralized laboratories toward rapid and decentralized testing formats. Growing demand for accurate diagnosis, antimicrobial-resistance surveillance, routine screening, and earlier treatment is encouraging healthcare systems to invest in molecular platforms, automated instruments, reagents, and laboratory services, supporting continued market development throughout the United States.
Hospitals and Sexual-Health Clinics as Major Testing Centers
USA STD Diagnostics Hospitals & Clinics Market represents an important distribution and service channel for STI testing because hospitals, outpatient centers, reproductive-health facilities, and specialized sexual-health clinics provide diagnostic services to diverse patient populations. More than 2.2 million cases of chlamydia, gonorrhea, and syphilis were reported in the United States in 2024, demonstrating the continuing need for accessible clinical testing. Hospitals and clinics commonly use laboratory-based molecular assays, serological tests, rapid diagnostic technologies, and specimen-collection systems. Testing is frequently integrated into primary care, prenatal care, emergency medicine, reproductive-health services, and dedicated STI programs. Clinics also play an important role in partner notification, treatment referral, and follow-up after positive results. Public-health departments and community health centers help extend diagnostic services to underserved populations and individuals facing financial or geographic barriers. Increasing adoption of digital appointments, rapid testing, self-collection, and decentralized diagnostic services is improving convenience. Consequently, sustained STI screening requirements and expanding preventive-care practices continue to generate demand for diagnostic services across U.S. hospitals and clinics.
California High STI Burden and Advanced Testing Infrastructure
California represents a major U.S. market for STD diagnostics because of its large population, diverse communities, and substantial STI burden. In 2023, California reported more than 167,000 chlamydia cases, 82,000 gonorrhea cases, and over 32,000 syphilis cases, creating strong demand for screening and diagnostic services. Major metropolitan areas, including Los Angeles and San Francisco, support extensive laboratory, hospital, and public-health infrastructure. California’s STD prevention programs increasingly utilize molecular diagnostics, rapid testing, and community-based screening to improve early detection. State and local health departments emphasize screening, partner services, education, and treatment, particularly among underserved populations. Community clinics and sexual-health organizations provide low-cost or publicly supported testing, while outreach programs help address stigma and improve awareness. California’s combination of advanced diagnostic technologies, large healthcare networks, and prevention initiatives supports continued market development. Increasing adoption of convenient testing and self-collection options is also expected to improve accessibility and encourage routine screening.
Texas Large Population and Significant Disease Burden
Texas is a significant market for STD diagnostics due to its large population, expanding metropolitan centers, and persistent STI burden. In 2023, Texas recorded approximately 142,000 chlamydia cases, 61,000 gonorrhea cases, and more than 24,000 syphilis cases, sustaining demand for screening and diagnostic technologies. Cities such as Houston, Dallas, San Antonio, and Austin have extensive healthcare facilities and specialized sexual-health services. Molecular testing and laboratory-based diagnostics are increasingly important for identifying infections that may not produce symptoms. Geographic disparities remain an important characteristic of the Texas market. Rural communities can face longer travel distances and fewer specialized testing facilities compared with major urban areas. Public health departments, federally supported clinics, mobile services, and community organizations help extend testing to underserved populations. Awareness campaigns encourage preventive screening and early treatment while addressing stigma surrounding STIs. Expanding decentralized and rapid diagnostic services could further improve accessibility. Consequently, the combination of population growth, urban healthcare investment, public-health initiatives, and demand for convenient testing supports STD diagnostics market growth across Texas.
New York Dense Urban Population and Established Healthcare Infrastructure
New York represents a prominent STD diagnostics market, supported by a large population, extensive healthcare infrastructure, and strong public-health programs. In 2023, New York State reported approximately 113,000 chlamydia cases, 38,000 gonorrhea cases, and more than 14,000 syphilis cases. New York City accounts for a substantial share of the state’s diagnostic demand because of its high population density and extensive network of hospitals, laboratories, sexual-health clinics, and community organizations. Molecular testing and laboratory-based screening are widely used for accurate detection. New York’s public-health initiatives emphasize screening among populations at elevated risk, partner notification, prevention education, and timely treatment. Public clinics and community organizations provide accessible testing services, helping reduce financial and social barriers. Digital appointment systems and convenient testing models further support diagnostic utilization. Rural and upstate communities, however, can experience comparatively limited access to specialized services. Continued investment in community outreach, sexual-health education, and decentralized diagnostics is therefore important. Strong healthcare infrastructure, targeted prevention programs, and sustained STI screening requirements position New York as an important U.S. market for STD diagnostic products and services.
Florida High Demand Driven by Population and STI Prevalence
Florida is a significant STD diagnostics market, supported by its large and growing population, extensive tourism activity, and persistent STI burden. In 2023, the state reported approximately 155,000 chlamydia cases, 65,000 gonorrhea cases, and more than 22,000 syphilis cases. Major population centers such as Miami, Orlando, Tampa, and Jacksonville generate substantial demand for testing through hospitals, laboratories, sexual-health clinics, and public-health facilities. Molecular diagnostics, serological testing, and rapid screening technologies are increasingly important for timely identification and management of infections. Florida’s health departments and community organizations conduct screening, education, prevention, and partner-services programs, particularly among higher-risk and underserved populations. However, differences in healthcare access between metropolitan and rural communities can limit consistent testing availability. Public awareness campaigns encourage regular screening and help address stigma associated with sexually transmitted infections. Expansion of mobile services, community-based testing, and convenient diagnostic technologies can improve coverage. The state’s large population, substantial testing requirements, healthcare infrastructure, and continued public-health initiatives are expected to support growth in the Florida STD diagnostics market.
United States STD Diagnostics Market Segments:
Test Type
- Chlamydia Testing
- Gonorrhea Testing
- Syphilis Testing
- HPV Testing
- HSV Testing
- HIV Testing
- Trichomonas Testing
- Mycoplasma genitalium Testing
- Chancroid Testing
Technology
- Immunoassay‐based Methods
- Molecular Diagnostics
- Next-Generation Sequencing
- Biosensor / Microfluidics & Other Emerging Platforms
Location of Testing
- Central & Hospital Laboratories
- Rapid Point-of-Care Platforms
- Over-the-Counter / Home Self-Testing
End User
- Hospitals & Clinics
- Diagnostic Laboratories
- Home Care / OTC
States – Market breakup in 29 viewpoints:
- California
- Texas
- New York
- Florida
- Illinois
- Pennsylvania
- Ohio
- Georgia
- New Jersey
- Washington
- North Carolina
- Massachusetts
- Virginia
- Michigan
- Maryland
- Colorado
- Tennessee
- Indiana
- Arizona
- Minnesota
- Wisconsin
- Missouri
- Connecticut
- South Carolina
- Oregon
- Louisiana
- Alabama
- Kentucky
- Rest of United States
All companies have been covered from 5 viewpoints:
- Company Overview
- Key Persons
- Recent Development & Strategies
- SWOT Analysis
- Sales Analysis
Key Players Analysis
- Abbott Laboratories
- F. Hoffmann-La Roche AG
- Hologic Inc.
- Becton Dickinson and Company
- Danaher Corporation (Cepheid)
- Siemens Healthineers AG
- bioMérieux SA
- Thermo Fisher Scientific Inc.
- Qiagen N.V.
- Bio-Rad Laboratories Inc.
Report Details:
| Report Features | Details |
| Base Year |
2025 |
| Historical Period |
2022 - 2025 |
| Forecast Period |
2026 - 2034 |
| Market |
US$ Billion |
| Segment Covered |
Test Type, Technology, Location of Testing, End User and States |
| States Covered |
|
| Companies Covered |
|
| Customization Scope |
20% Free Customization |
| Post-Sale Analyst Support |
1 Year (52 Weeks) |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
Customization Services available
- Analysis of Market Size and Its Segments
- More Company Profiles (Upto 10 without any additional cost):
- Additional Countries (Other than mentioned Countries):
- Region/Country Specific Reports:
- Market Entry Strategy:
- Region-Specific Market Dynamics:
- Regional Market Share Analysis:
- Trade Analysis:
- Production Insights:
- Others Customized Requests:
For more information contact our analysts.
Need More Assistance?
- Talk to our analysts to get more precious information on the current market trends.
- Include more countries and segments and customize the report based on the final requirement.
- Get a competitive advantage in your industry by knowing the report findings and making a positive impact on your revenues and operations.
- Our analysts are always ready to provide more help and pertinent information if you need any additional assistance.
1. Introduction
2. Research & Methodology
2.1 Data Source
2.1.1 Primary Sources
2.1.2 Secondary Sources
2.2 Research Approach
2.2.1 Top-Down Approach
2.2.2 Bottom-Up Approach
2.3 Forecast Projection Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. United States STD Diagnostics Market
5.1 Historical Market Trends
5.2 Market Forecast
6. Market Share Analysis
6.1 By Test Type
6.2 By Technology
6.3 By Location of Testing
6.4 By End User
6.5 By States
7. Test Type
7.1 Chlamydia Testing
7.1.1 Market Analysis
7.1.2 Market Size & Forecast
7.2 Gonorrhea Testing
7.2.1 Market Analysis
7.2.2 Market Size & Forecast
7.3 Syphilis Testing
7.3.1 Market Analysis
7.3.2 Market Size & Forecast
7.4 HPV Testing
7.4.1 Market Analysis
7.4.2 Market Size & Forecast
7.5 HSV Testing
7.5.1 Market Analysis
7.5.2 Market Size & Forecast
7.6 HIV Testing
7.6.1 Market Analysis
7.6.2 Market Size & Forecast
7.7 Trichomonas Testing
7.7.1 Market Analysis
7.7.2 Market Size & Forecast
7.8 Mycoplasma genitalium Testing
7.8.1 Market Analysis
7.8.2 Market Size & Forecast
7.9 Chancroid Testing
7.9.1 Market Analysis
7.9.2 Market Size & Forecast
8. Technology
8.1 Immunoassay‐based Methods
8.1.1 Market Analysis
8.1.2 Market Size & Forecast
8.2 Molecular Diagnostics
8.2.1 Market Analysis
8.2.2 Market Size & Forecast
8.3 Next-Generation Sequencing
8.3.1 Market Analysis
8.3.2 Market Size & Forecast
8.4 Biosensor / Microfluidics & Other Emerging Platforms
8.4.1 Market Analysis
8.4.2 Market Size & Forecast
9. Location of Testing
9.1 Central & Hospital Laboratories
9.1.1 Market Analysis
9.1.2 Market Size & Forecast
9.2 Rapid Point-of-Care Platforms
9.2.1 Market Analysis
9.2.2 Market Size & Forecast
9.3 Over-the-Counter / Home Self-Testing
9.3.1 Market Analysis
9.3.2 Market Size & Forecast
10. End User
10.1 Hospitals & Clinics
10.1.1 Market Analysis
10.1.2 Market Size & Forecast
10.2 Diagnostic Laboratories
10.2.1 Market Analysis
10.2.2 Market Size & Forecast
10.3 Home Care / OTC
10.3.1 Market Analysis
10.3.2 Market Size & Forecast
11. Top States
11.1 California
11.1.1 Market Analysis
11.1.2 Market Size & Forecast
11.2 Texas
11.2.1 Market Analysis
11.2.2 Market Size & Forecast
11.3 New York
11.3.1 Market Analysis
11.3.2 Market Size & Forecast
11.4 Florida
11.4.1 Market Analysis
11.4.2 Market Size & Forecast
11.5 Illinois
11.5.1 Market Analysis
11.5.2 Market Size & Forecast
11.6 Pennsylvania
11.6.1 Market Analysis
11.6.2 Market Size & Forecast
11.7 Ohio
11.7.1 Market Analysis
11.7.2 Market Size & Forecast
11.8 Georgia
11.8.1 Market Analysis
11.8.2 Market Size & Forecast
11.9 New Jersey
11.9.1 Market Analysis
11.9.2 Market Size & Forecast
11.10 Washington
11.10.1 Market Analysis
11.10.2 Market Size & Forecast
11.11 North Carolina
11.11.1 Market Analysis
11.11.2 Market Size & Forecast
11.12 Massachusetts
11.12.1 Market Analysis
11.12.2 Market Size & Forecast
11.13 Virginia
11.13.1 Market Analysis
11.13.2 Market Size & Forecast
11.14 Michigan
11.14.1 Market Analysis
11.14.2 Market Size & Forecast
11.15 Maryland
11.15.1 Market Analysis
11.15.2 Market Size & Forecast
11.16 Colorado
11.16.1 Market Analysis
11.16.2 Market Size & Forecast
11.17 Tennessee
11.17.1 Market Analysis
11.17.2 Market Size & Forecast
11.18 Indiana
11.18.1 Market Analysis
11.18.2 Market Size & Forecast
11.19 Arizona
11.19.1 Market Analysis
11.19.2 Market Size & Forecast
11.20 Minnesota
11.20.1 Market Analysis
11.20.2 Market Size & Forecast
11.21 Wisconsin
11.21.1 Market Analysis
11.21.2 Market Size & Forecast
11.22 Missouri
11.22.1 Market Analysis
11.22.2 Market Size & Forecast
11.23 Connecticut
11.23.1 Market Analysis
11.23.2 Market Size & Forecast
11.24 South Carolina
11.24.1 Market Analysis
11.24.2 Market Size & Forecast
11.25 Oregon
11.25.1 Market Analysis
11.25.2 Market Size & Forecast
11.26 Louisiana
11.26.1 Market Analysis
11.26.2 Market Size & Forecast
11.27 Alabama
11.27.1 Market Analysis
11.27.2 Market Size & Forecast
11.28 Kentucky
11.28.1 Market Analysis
11.28.2 Market Size & Forecast
11.29 Rest of United States
11.29.1 Market Analysis
11.29.2 Market Size & Forecast
12. Value Chain Analysis
13. Porter's Five Forces Analysis
13.1 Bargaining Power of Buyers
13.2 Bargaining Power of Suppliers
13.3 Degree of Competition
13.4 Threat of New Entrants
13.5 Threat of Substitutes
14. SWOT Analysis
14.1 Strength
14.2 Weakness
14.3 Opportunity
14.4 Threats
15. Merger and Acquisition
16. Key Players Analysis
16.1 Abbott Laboratories
16.1.1 Overviews
16.1.2 Key Person
16.1.3 Recent Developments
16.1.4 SWOT Analysis
16.1.5 Revenue Analysis
16.2 F. Hoffmann-La Roche AG
16.2.1 Overviews
16.2.2 Key Person
16.2.3 Recent Developments
16.2.4 SWOT Analysis
16.2.5 Revenue Analysis
16.3 Hologic Inc.
16.3.1 Overviews
16.3.2 Key Person
16.3.3 Recent Developments
16.3.4 SWOT Analysis
16.3.5 Revenue Analysis
16.4 Becton Dickinson and Company
16.4.1 Overviews
16.4.2 Key Person
16.4.3 Recent Developments
16.4.4 SWOT Analysis
16.4.5 Revenue Analysis
16.5 Danaher Corporation (Cepheid)
16.5.1 Overviews
16.5.2 Key Person
16.5.3 Recent Developments
16.5.4 SWOT Analysis
16.5.5 Revenue Analysis
16.6 Siemens Healthineers AG
16.6.1 Overviews
16.6.2 Key Person
16.6.3 Recent Developments
16.6.4 SWOT Analysis
16.6.5 Revenue Analysis
16.7 bioMérieux SA
16.7.1 Overviews
16.7.2 Key Person
16.7.3 Recent Developments
16.7.4 SWOT Analysis
16.7.5 Revenue Analysis
16.8 Thermo Fisher Scientific Inc.
16.8.1 Overviews
16.8.2 Key Person
16.8.3 Recent Developments
16.8.4 SWOT Analysis
16.8.5 Revenue Analysis
16.9 Qiagen N.V.
16.9.1 Overviews
16.9.2 Key Person
16.9.3 Recent Developments
16.9.4 SWOT Analysis
16.9.5 Revenue Analysis
16.10 Bio-Rad Laboratories Inc.
16.10.1 Overviews
16.10.2 Key Person
16.10.3 Recent Developments
16.10.4 SWOT Analysis
16.10.5 Revenue Analysis
Reach out to us
Call us on
USA: +1-478-202-3244
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com